HCID 44467820, compound → HCID 44467950, compound

HRID 2381659Notes

Reaction equation

HRID 2381659 reaction equation
[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[N:12]=[C:13]([NH:20][CH:21]4[CH2:26][CH2:25][N:24](C(OC(C)(C)C)=O)[CH2:23][CH2:22]4)[C:14]4[CH:19]=[CH:18][NH:17][C:15]=4[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1>C(O)(C(F)(F)F)=O>[NH:1]1[C:9]2[C:4](=[CH:5][CH:6]=[C:7]([NH:10][C:11]3[N:12]=[C:13]([NH:20][CH:21]4[CH2:26][CH2:25][NH:24][CH2:23][CH2:22]4)[C:14]4[CH:19]=[CH:18][NH:17][C:15]=4[N:16]=3)[CH:8]=2)[CH:3]=[N:2]1

Participants

3

Reactant 1

HCID 44467820HCID 44467820, compound

Product 1

HCID 44467950HCID 44467950, compoundYield 31.9%

Reagents, catalysts & solvents 1

HCID 6422Trifluoroacetic acidSolvent

Procedure

A solution of tert-butyl 4-(2-(1H-indazol-6-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)piperidine-1-carboxylate (4 mg, 0.009 mmol) in TFA (1 mL) was stirred at room temperature for 2 h. It was concentrated in vacuo. The residue was purified by reverse phase HPLC using a gradient of 3-30% CH3CN in water over 10 min. as eluents to give a powder (1 mg). MS 349.0 (M+H); UV 201.4, 242.6, 306.7 nm.

Workup

  1. concentrationIt was concentrated in vacuo
  2. customThe residue was purified by reverse phase HPLC
  3. customover 10 min.

Sources & evidence

ORD record
ord-19ba651db85e4384a488421e7f533a8e
Source dataset
uspto-grants-2012_09
Patent number
US08258144B2

Reaction notes

Loading…